奕瑞科技公告，2024年营业收入18.31亿元，同比下降1.74%。归属于上市公司股东的净利润4.65亿元， 同比下降23.43%。公司2024年年度利润分配及资本公积转增股本方案为：公司拟向全体股东每10股派 发现金红利10元(含税)，合计拟派发现金红利1.43亿元(含税)；以资本公积向全体股东每10股转增4股， 转增后公司总股本将增加至2亿股。 ...

奕瑞科技公告，2025年第一季度营收为4.82亿元，同比下降1.92%；净利润为1.43亿元，同比增长 2.74%。 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-020 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于持股 5%以上股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 奕瑞电子科技集团股份有限公司（以下简称"公司"）股东海南合毅投资 有限公司（以下简称"海南合毅"）直接持有公司股份 12,745,547 股，占公司总 股本的 8.91%。 本次质押后，公司股东海南合毅累计质押公司股份 1,500,000 股，占其持 股总数的 11.77%，占公司总股本的 1.05%。 一、本次股份质押情况 公司于近日接到持股 5%以上股东海南合毅的通知，获悉其将所持有的本公 司部分股份对第三方质押，质权人为中原信托有限公司，具体事项如下： | 股东名称 | 是否为 控股股 | 本次质押 | 是否 为限 | 是否补 | 质押起 | 质押到 | 质权人 | 占其所 持股份 | 占公司 总股 ...

| 证券代码：688301 | 证券简称：奕瑞科技 公告编号：2025-019 | | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | 奕瑞电子科技集团股份有限公司 关于不向下修正"奕瑞转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 截至2025年4月17日，奕瑞电子科技集团股份有限公司（以下简称"公司"） 股价已触发"奕瑞转债"转股价格向下修正条款。 经公司第三届董事会第十三次会议审议通过，公司董事会决定本次不向下 修正转股价格，同时在未来三个月内即本公告披露日至2025年7月17日，如再次 触发"奕瑞转债"转股价格的向下修正条款，亦不提出向下修正方案。 一、可转换公司债券基本情况 经中国证券监督管理委员会《关于同意上海奕瑞光电子科技股份有限公司向 不特定对象发行可转债注册的批复》（证监许可[2022]2167 号）同意注册，公司 向不特定对象共计发行 14,350,100 张可转换公司债券，每张面值为人民币 100 元，按面值发行，本次发行可转债募集资 ...

上海市方达律师事务所 关于奕瑞电子科技集团股份有限公司 向特定对象发行 A 股股票的 | 一、奕瑞韩国诉讼的最新进展情况及可能的法律后果 4 | | --- | | 二、奕瑞韩国诉讼不属于《注册管理办法》第十一条列举的不得向特定对象 | | 发行股票的情形 5 | | 三、奕瑞韩国诉讼不会对本次发行构成实质性法律障碍 11 四、请律师对上述事项核查并发表明确意见 13 | 7-4-17-1 上海市方达律师事务所 补充法律意见书（三） 补充法律意见书（三） 2025 年 4 月 目 录 FANGDA PARTNERS http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: +86-21-2208 1166 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai, PRC 200041 上海市方达律师事务所 关于 ...

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.94倍，行业中值29.64倍，奕瑞科技排 名第79位。 4月16日，奕瑞科技今日收盘125.4元，下跌1.07%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到35.84倍，总市值179.40亿元。 奕瑞电子科技集团股份有限公司的主营业务是数字化X线探测器、高压发生器、组合式射线源、球管等 新核心部件的研发、生产、销售与服务。报告期内，公司量产的产品包括平板探测器和线阵探测器，并 已掌握非晶硅、IGZO、CMOS和柔性基板四大传感器技术，为公司进一步丰富产品线、服务多领域客 户、提高市场竞争力与品牌影响力打下坚实的基础。 来源：金融界 截至2024年三季报，共有269家机构持仓奕瑞科技，其中基金269家，合计持股数3290.46万股，持股市 值31.45亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入13.56亿元，同比-2.91%；净利润3.90亿元，同 比-9.88%，销售毛利率54.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)79奕瑞科技35.8435.844.14179.40亿行业平均 45.94 ...

Investment Rating - The report maintains an "Outperform" rating for the machinery equipment industry [5]. Core Views - The humanoid robot sector is rapidly advancing, with Tesla's humanoid robot aiming for mass production of 5,000 units by 2025. Domestic companies like Yushutech and ZhiYuan Robotics are also innovating quickly, focusing on key components such as reducers and sensors [3][4]. - AI infrastructure is experiencing growth driven by demand for data centers, benefiting companies involved in cooling systems [4]. - The low-altitude economy is progressing with infrastructure initiatives, aiming to create a unified air traffic management network [4]. Industry Dynamics - Humanoid Robots: Recent demonstrations include the release of a dexterous hand technology by Xingdong Era and a boxing video by Yushutech [1][18]. - Smart Welding: The application of pipeline welding robots by China National Petroleum has achieved scale [20]. - Low-altitude Economy: New companies and initiatives are being established to support the development of low-altitude economic infrastructure [21][26]. Company Dynamics - Yushutech and Chang'an Automobile signed a strategic cooperation agreement to collaborate on robotics technology [31]. - ZhiYuan Robotics participated in a roundtable discussion on economic trends [22]. - A joint venture was established between Junpu Intelligent and ZhiYuan Robotics to focus on humanoid robots [29]. Event Outlook - A humanoid robot half-marathon is scheduled to take place in Beijing on April 19, 2025, featuring humanoid robots competing alongside human participants [37]. Key Company Profit Forecasts and Investment Ratings - Companies such as Lide Harmony, Mingzhi Electric, and Huichuan Technology are rated as "Outperform" with various earnings per share (EPS) forecasts for 2023 and 2024 [9].

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-018 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于子公司诉讼进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、本次诉讼的进展 近日，奕瑞韩国及其代表理事收到首尔高等法院出具的二审《判决书》（案 件号：2024NO3975），检察官对被告即奕瑞韩国及其代表理事提出的所有上诉请 求被驳回，奕瑞韩国及其代表理事无罪。 2024 年 4 月，奕瑞电子科技集团股份有限公司（原名"上海奕瑞光电子科技 股份有限公司"，以下简称"公司"或"奕瑞科技"）全资子公司奕瑞韩国及其代表理 事收到了首尔中央地方检察厅向首尔中央地方法院提交的《公诉状》（2023 年刑 第 38512 号）。具体情况详见公司于 2024 年 4 月 9 日在上海证券交易所网站 （www.sse.com.cn）披露的《奕瑞科技关于子公司涉及诉讼的公告》（公告编号： 2024-015）。 ...

Investment Rating - The industry investment rating is "Outperform the Market" [52] Core Views - The report emphasizes the ongoing disruptions caused by the US-China tariff policies and suggests focusing on opportunities in non-US markets and import substitution [4][9] - The report highlights that the adjustment of tariffs is expected to impact the trade of pharmaceutical products between China and the US, while companies primarily exporting to markets outside the US will be less affected [4][9] Summary by Sections Tariff Policy Overview - Since April 2, 2025, the US government has imposed a 34% "reciprocal tariff" on Chinese goods, with frequent adjustments to tariff rates and exemptions for certain pharmaceutical products [4][5] - As of April 11, 2025, the tariff rates for bilateral trade between China and the US have been adjusted to 125%, with China indicating it will not respond to further tariff increases from the US [5] Opportunities in the Biopharmaceutical Sector - The report identifies potential for domestic products to increase market share in the blood products sector due to tariff impacts, particularly for albumin, where US imports are significant [9] - It suggests monitoring companies such as Palin Bio, Tiantan Bio, and Huashan Bio for potential growth in market share as import costs rise [9] Medical Devices - The report notes that the tariff policies and anti-dumping investigations are likely to accelerate the domestic substitution process in medical devices, particularly in electrophysiology and imaging fields [10] - Companies like Yirui Technology and United Imaging are highlighted as making progress in domestic production capabilities [10] Investment Strategies - The report recommends focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumption recovery" as key investment themes [12] - Specific companies to watch include BeiGene, Mindray, and Xiamen Innovax for their innovative products and overseas market potential [12] Key Companies to Watch - Notable companies include: - **Nocera Biopharma**: Expected to achieve significant revenue growth with its core product, demonstrating strong cash flow and reduced losses [13][14] - **Sino Biopharmaceutical**: Rapid revenue growth with a focus on innovative products and a strong pipeline [18] - **Kexing Biopharma**: Stable domestic business with promising overseas expansion [18] - **Wuxi Biologics**: Recognized for its strong technical capabilities and expanding overseas operations [22] Market Performance - The report notes a decline in the pharmaceutical sector, with a 5.61% drop in the past week, while the overall market saw a smaller decline [31][42] - The biopharmaceutical sector is highlighted as having the smallest decline among sub-sectors, indicating relative resilience [44]

Investment Rating - The report maintains a "Hold" rating for the healthcare sector [8] Core Viewpoints - The pharmaceutical sector slightly underperformed the CSI 300 index, with a decline of 5.61% from April 7 to April 11, 2025, ranking 22nd among 31 sectors [3][13] - Year-to-date, the pharmaceutical index has decreased by 1.10%, outperforming the CSI 300 index by 3.59 percentage points, ranking 13th among 31 sectors [15] - As of April 11, 2025, the valuation of the pharmaceutical sector stands at 25.91 times (TTM overall method, excluding negative values), with a premium of 141.73% compared to the CSI 300 index [18] Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 7 to April 11, 2025, shows a decline of 5.61%, underperforming the CSI 300 index by 2.74 percentage points [3][13] - The valuation level of the pharmaceutical sector is reported at 25.91 times, with a significant premium over the CSI 300 index [18] - Top-performing stocks include Yirui Technology (+20.54%), Yipinhong (+17.03%), and Yong'an Pharmaceutical (+13.93%) [19][20] 2. Important Policies and Events - On April 7, 2025, the Ministry of Commerce and the National Health Commission, along with 12 other departments, issued the "Special Action Plan for Promoting Healthy Consumption" to enhance the quality of health goods and services [5][22] 3. Important Company Announcements - Haizike reported a revenue of 3.721 billion yuan for 2024, a year-on-year increase of 10.92%, with a net profit of 395 million yuan, up 34.00% [23] - Kexing Pharmaceutical announced a revenue of 1.407 billion yuan for 2024, with a net profit of 31 million yuan, marking a return to profitability [23] 4. Industry Perspectives - The report discusses the impact of the ongoing trade war, noting that while pharmaceuticals were initially included in tariff discussions, they were later excluded from the "reciprocal tariffs" announced by the U.S. government [6][25] - The report highlights that increased tariffs on imports from the U.S. could benefit domestic substitutes in the blood products, high-end medical devices, and innovative drug sectors [6][26]